Form 8-K - Current report:
SEC Accession No. 0000950170-25-070287
Filing Date
2025-05-13
Accepted
2025-05-13 16:03:48
Documents
11
Period of Report
2025-05-13
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K lrmr-20250513.htm   iXBRL 8-K 56939
  Complete submission text file 0000950170-25-070287.txt   167517

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lrmr-20250513.xsd EX-101.SCH 23893
13 EXTRACTED XBRL INSTANCE DOCUMENT lrmr-20250513_htm.xml XML 4533
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

EIN.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36510 | Film No.: 25939891
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)